The non-exclusive patent license agreement allows Mankind Pharma to commercialise Vonoprazan, a potassium-competitive acid blocker (P-CAB), for the treatment of Gastroesophageal Reflux Disease (GERD) and other acid-related disorders
Read More_20240705093815_original_image_8.webp)
From streamlining administrative processes to enhancing the accuracy of medical record keeping, the potential applications of this technology are vast and impactful, thereby eliminating risk to patient safety
Read More
Data suggests that 1.2 million deaths in India are due to antimicrobial resistance (AMR), with an estimated 10 million deaths by 2050
Read More
